Patient recruitment is an essential part of a successful trial. Patients must understand the rationale for the study, and be open to participating. All patients must give informed consent to participate. Trial protocols must be approved by the local institutional review board, and all trial participants must sign an informed consent document prior to enrollment in the trial. Investigators must follow rigorous standards for trial conduct and reporting of results, including timely publication of final reports.
Gallium Ga 68 gozetotide should therefore only be used when standard imaging techniques fail to find an appropriate lesion. It should be reserved as an adjunct to conventional imaging modalities, particularly PET/CT.
The discovery of targeted therapies and immunotherapies as well as novel chemotherapeutic approaches will hopefully lead to an improvement in cancer treatments in the near future. However, these advancements have not yet significantly impacted clinical practice. Current studies are showing that many tumors still do not respond to therapy. As prediction of treatment response becomes more accurate, new questions arise regarding which patient should receive treatment and/or which treatment regimen should be used.
Results from a recent paper indicate that Ga68-Gozetatide is well tolerated and produces significant tracer uptake in lung metastases from breast carcinoma. No advantage was seen in terms of disease progression and survival in patients treated with Ga68-Gozetatide compared with those receiving a placebo. Further studies are warranted to determine if certain subgroups of patients would benefit from Ga68-Gozetatide therapy.
The mean duration of gallium administration was 4.7 days with no serious adverse events reported. No significant changes were found in kidney function or blood chemistry parameters.
These data support the need for standardization of treatment regimens, particularly in advanced disease. Cancer treatment typically consists of surgery, radiation, chemotherapy, targeted therapy, immunotherapy and hormonal agents. We found no evidence based on which of these treatments were most commonly used. Patient-centered care programs should consider including information about currently available treatments.
Gallium Ga-68 GZT improved QoL as measured by the EORTC QLQ-C30 as compared to placebo. Although these results indicate superiority of Ga-68 GZT over Ga-68 Gd-DTPA as a diagnostic and/or therapeutic agent, the QoL improvement observed may not necessarily translate into increased survival.
People younger than 45 years of age have higher chances of developing cancer compared to those older than 45 years. Male gender and high blood pressure are associated with developing cancer. Increasing blood cholesterol levels and smoking are risk factors for menopause. High blood pressure and diabetes mellitus are risk factors for women.
Findings from a recent study suggest that between 250,000 and 5 million new cases of cancer occur each year in the US. Most cancers are common diseases that occur spontaneously rather than being caused by exposure to environmental agents. Findings from a recent study provide useful information for health planners and policy makers who need estimates of new cases of specific types of cancer and disease.